Actavis extends Concerta distribution agreement with Janssen
The supply and distribution agreement was first agreed to by the companies in November 2010 and is due to expire on 31 December 2014. As part of the
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.